Consistently, PD-1 (Programmed Cell Death Protein 1) and its ligand (PD-L1) inhibitors have been approved by FDA and have been shown to be quite effective in several neoplasms, including leukemia [4]. This evidence concerns the gene PDCD1 and neoplasm.